Novartis for MANF in the diabetes field is also a possibility.
Uplisting to the NASDAQ in 2014.
So much potential for less than a dime. :)
p.s. Shorts are doomed. :(
yes....novartis would expect the same accountant upgrade as BD...but i dont think gerald wants to get ahead of himself...lympro first has been their game plan....